ACCELERON PHARMA INC's ticker is XLRN and the CUSIP is 00434H108. A total of 242 filers reported holding ACCELERON PHARMA INC in Q3 2020. The put-call ratio across all filers is 0.80 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2021 | $255,568,000 | +160.4% | 1,485 | +89.9% | 0.00% | – |
| Q2 2021 | $98,133,000 | +839.8% | 782 | +915.6% | 0.00% | – |
| Q1 2021 | $10,442,000 | -95.5% | 77 | -95.7% | 0.00% | – |
| Q4 2020 | $229,908,000 | +70.3% | 1,797 | +49.8% | 0.00% | – |
| Q3 2020 | $135,036,000 | -96.7% | 1,200 | -97.2% | 0.00% | -100.0% |
| Q2 2020 | $4,132,146,000 | +131.5% | 43,373 | +118.4% | 0.01% | +75.0% |
| Q1 2020 | $1,784,728,000 | +430.4% | 19,859 | +212.9% | 0.00% | +300.0% |
| Q4 2019 | $336,465,000 | +5.2% | 6,346 | -21.6% | 0.00% | 0.0% |
| Q3 2019 | $319,833,000 | +31.2% | 8,095 | +36.5% | 0.00% | – |
| Q2 2019 | $243,687,000 | -48.5% | 5,932 | -41.6% | 0.00% | -100.0% |
| Q1 2019 | $472,732,000 | +1149.1% | 10,151 | +1068.1% | 0.00% | – |
| Q4 2018 | $37,845,000 | -69.6% | 869 | -60.0% | 0.00% | – |
| Q3 2018 | $124,475,000 | +53.0% | 2,175 | +29.7% | 0.00% | – |
| Q2 2018 | $81,368,000 | -73.2% | 1,677 | -78.4% | 0.00% | -100.0% |
| Q1 2018 | $303,768,000 | -7.4% | 7,769 | +0.5% | 0.00% | 0.0% |
| Q4 2017 | $328,061,000 | +157.5% | 7,730 | +126.4% | 0.00% | – |
| Q3 2017 | $127,410,000 | +15.6% | 3,414 | -5.9% | 0.00% | – |
| Q2 2017 | $110,225,000 | +1128.4% | 3,627 | +969.9% | 0.00% | – |
| Q1 2017 | $8,973,000 | -80.8% | 339 | -81.5% | 0.00% | – |
| Q4 2016 | $46,676,000 | -39.2% | 1,829 | -13.8% | 0.00% | – |
| Q3 2016 | $76,759,000 | +109.2% | 2,121 | +96.4% | 0.00% | – |
| Q2 2016 | $36,698,000 | -82.5% | 1,080 | -74.9% | 0.00% | -100.0% |
| Q4 2015 | $209,570,000 | +84.5% | 4,298 | -5.8% | 0.00% | – |
| Q3 2015 | $113,569,000 | +86.6% | 4,561 | +137.1% | 0.00% | – |
| Q2 2015 | $60,875,000 | +308.0% | 1,924 | +390.8% | 0.00% | – |
| Q1 2015 | $14,920,000 | -44.5% | 392 | -55.9% | 0.00% | – |
| Q3 2014 | $26,883,000 | +11101.2% | 889 | +12600.0% | 0.00% | – |
| Q1 2014 | $240,000 | -92.3% | 7 | -91.1% | 0.00% | – |
| Q4 2013 | $3,128,000 | – | 79 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Darwin Global Management, Ltd. | 938,490 | $120,070,000 | 33.50% |
| Foresite Capital Management III, LLC | 108,630 | $13,898,000 | 16.15% |
| Octagon Capital Advisors LP | 112,363 | $14,376,000 | 4.98% |
| Artal Group S.A. | 1,400,000 | $179,116,000 | 3.84% |
| Avoro Capital Advisors LLC | 1,550,000 | $198,307,000 | 3.42% |
| Affinity Asset Advisors, LLC | 45,000 | $5,757,000 | 3.05% |
| NWI MANAGEMENT LP | 200,000 | $25,588,000 | 2.54% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 71,000 | $9,063,000 | 2.48% |
| FARALLON CAPITAL MANAGEMENT LLC | 2,600,000 | $332,644,000 | 2.00% |
| Parkman Healthcare Partners LLC | 52,458 | $6,711,000 | 1.72% |